New Delhi, Oct. 3 -- The White House sells savings while insurers and PBMs sharpen their knives.

WASHINGTON - The White House on Tuesday unveiled a two-part bid to dent America's punishing prescription costs: a headline agreement with Pfizer to extend "most-favored-nation" pricing to state Medicaid programs, and a forthcoming federal portal, "TrumpRx," that will steer consumers to sharply discounted, manufacturer-run purchase pages. The gambit pairs the promise of lower out-of-pocket costs with hard-edged leverage on industry, including the threat of sweeping import tariffs that could climb to triple digits for brand-name drugs made abroad. Whether families feel real relief at the pharmacy will turn on the plumbing - who participates, wh...